From Oct. 27, 2014 - "As a holding company, Amaran
Post# of 30026
Posted On: 12/22/2014 11:59:13 AM
Re: brickbybrick #13600
From Oct. 27, 2014 - "As a holding company, Amarantus is continuing to evaluate methods of returning value to shareholders, including a potential spinoff of the company’s diagnostic division. In addition to LymPro and our NuroPro Parkinson’s diagnostic, we are actively evaluating additional complementary late-stage neurology-focused diagnostic assets that would bolster our diagnostic division and make for a successful ‘spin-out’ while concurrently returning value to our shareholders. We believe we will be able to execute on this strategy in the near-term."
"assets" Plural
Should be an interesting week and month ahead.
"assets" Plural
Should be an interesting week and month ahead.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼